Biotechnology News and Research RSS Feed - Biotechnology News and Research

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

Gene therapy is the delivery of DNA into a patient's cells to replace faulty or missing genes—or adds new genes—in an attempt to cure cancer or make changes so the body is better able to fight off disease. Scientists and clinicians have identified a number of different ways to do this, in an effort to correct malfunctioning or mutated genes. Many gene therapy clinical trials are ongoing to assess the safety and potential benefits in patients with rare diseases. [More]
Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas. [More]
Comprehensive stroke centers reduce mortality risk in patients treated for hemorrhagic stroke

Comprehensive stroke centers reduce mortality risk in patients treated for hemorrhagic stroke

New research published today in the Journal of the American Heart Association indicates that patients who are treated for hemorrhagic stroke at a comprehensive stroke center are more likely to receive specialized treatment, reducing the risk of mortality. [More]
Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers. [More]
Adelaide researchers identify target for developing new antibiotics against disease-causing bacteria

Adelaide researchers identify target for developing new antibiotics against disease-causing bacteria

University of Adelaide researchers have discovered a target for the development of completely new antibiotics against disease-causing bacteria. [More]
Partners congratulate researchers on forming new biotechnology company

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system. [More]
Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers. [More]
Metal oxide nanoparticles induce changes in human colon

Metal oxide nanoparticles induce changes in human colon

Exposure of a model human colon to metal oxide nanoparticles, at levels that could be present in foods, consumer goods, or treated drinking water, led to multiple, measurable differences in the normal microbial community that inhabits the human gut. [More]
Bio-Techne's net sales increase 19% to $114.2 million in third quarter 2015

Bio-Techne's net sales increase 19% to $114.2 million in third quarter 2015

Bio-Techne Corporation today reported its financial results for the third quarter ended March 31, 2015. [More]
Researchers identify mechanism responsible for steroid resistance in leukemia patients

Researchers identify mechanism responsible for steroid resistance in leukemia patients

Researchers led by St. Jude Children's Research Hospital scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases. [More]
Study provides insight into the brain structures affected by epilepsy

Study provides insight into the brain structures affected by epilepsy

Epilepsy, a disorder characterized by abnormal neuronal activity in certain regions of the brain, leads to organizational changes that can alter brain efficiency at the level of the whole brain. This occurs across functional networks that connect different brain regions and within individual brain regions, as described in an article in Brain Connectivity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
AMSBIO launches new and exclusive biotinylated protein collection

AMSBIO launches new and exclusive biotinylated protein collection

AMSBIO has launched a new and exclusive biotinylated protein collection specially designed to simplify your research. [More]
Better interventions needed to improve outcomes in young breast cancer patients

Better interventions needed to improve outcomes in young breast cancer patients

Breast cancer that occurs in young women is likely to be more aggressive and to require more intensive types of therapy with increased risk of long-term treatment-related toxicities. The unique and significant challenges and psychosocial concerns that women under 40 years of age with breast cancer face are discussed in a special article published in Journal of Adolescent and Young Adult Oncology, a multidisciplinary peer-reviewed publication from, Mary Ann Liebert, Inc., publishers. [More]
Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. [More]
Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. [More]
Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its TransCon technology to address significant unmet medical needs, announced today that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations. [More]
Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. [More]
Gladstone researchers identify way to prevent MS development in mice

Gladstone researchers identify way to prevent MS development in mice

Scientists from the Gladstone Institutes have discovered a way to prevent the development of multiple sclerosis (MS) in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation and autoimmunity, the researchers successfully protected against the onset of MS in an animal model of the disease. [More]

NASP, SmartBrief partner to launch first news brief dedicated to specialty pharmacy industry

The National Association of Specialty Pharmacy and SmartBrief recently partnered to deliver a daily newsletter providing the specialty pharmacy industry with a snapshot of the top news in the industry. [More]

Multichannel Pipette accelerates sample screening and genotyping assays INTEGRA

INTEGRA has published a new customer video from the Institute of Clinical Chemistry research group at the Technical University of Munich (TUM), in which researcher Christina Thomas reviews how the VOYAGER multichannel pipette has accelerated their sample screening and genotyping assays. [More]
Advertisement
Advertisement